The sales myth of new crown drugs

Author: Shi Bei

The outbreak of the new crown epidemic has brought about "earth-shaking" changes to the world.

In China, ABBio, which has the concept of mRNA, also completed a Series C financing with a total amount of more than US$700 million in less than 4 months, breaking the record of a single financing before the IPO of a Chinese biopharmaceutical company

According to the NextPharma database of Medicine Rubik’s Cube, there are currently as many as 20 drugs for the prevention/treatment of new crown diseases that have been approved by regulatory agencies, emergency use authorization (EUA)/temporary supply in China, the United States, Europe, Japan and other countries, including 11 vaccines.

Drugs used in China, the United States, Europe and Japan to prevent and treat the new crown

Note: India approved the first new coronavirus DNA vaccine ZyCoV-D on August 20

Judging from the company's disclosed mid-year performance, the sales revenue of these new crown drugs in the first half of 2021 totaled US$27.

Note: BioNTech is responsible for the sales of vaccines in Germany and Turkey.

With such attractive market returns, the development of new crown therapeutic drugs on a global scale is naturally in full swing, including vaccines, neutralizing antibodies, and oral drug projects of many Chinese companies are also accelerating to the goal of phase III and listing

Some Chinese New Coronary Drugs Under Development

Abbio/Watson Bio-mRNA vaccine ARCoVaX

ARCoVaX was originally developed by Abbio.

INOVIO/ Ai Di Weixin DNA vaccine INO-4800

INO-4800 was developed by Ai Di Weixin in cooperation with INOVIO

On January 4 this year, US INOVIO and Ai Di Weixin reached a further cooperation and licensing agreement on INO-4800.

Clover recombinant protein new crown vaccine SCB-2019

SCB-2019 is a clover biological application Trimer-Tag© (protein trimerization) technology platform developed SCB-2019 antigen (a stable trimeric structural fusion protein based on SARS-CoV-2 virus S protein) and added CpG Recombinant protein new crown vaccine with 1018 adjuvant and aluminum hydroxide adjuvant

SCB-2019's global pivotal Phase II/III clinical trial SPECTRA completed the enrollment of middle-aged and elderly subjects as planned on July 6.

Livzon Pharmaceuticals recombinant new coronavirus fusion protein vaccine V-01

V-01 has been established for research and development since July 2020.

Tengshengbo drug neutralizing antibody BRII-196/BRII-198

BRII-196 and BRII-198 are non-competitive SARS-CoV-2 monoclonal neutralizing antibodies obtained from COVID-19 patients during the convalescence period, and specifically apply genetic engineering technology to reduce the risk of antibody-mediated dependence enhancement.

The China Phase II trial of the BRII-196/BRII-198 combination therapy is currently underway, led by Academician Zhong Nanshan

Boan Biological Neutralizing Antibody LY-CovMab

LY-CovMab is developed by Boan Biotech’s fully human antibody transgenic mice and phage display technology platform.

Pakrulamide

Prokramide is a new generation of androgen receptor antagonist independently developed by the pioneering pharmaceutical industry.

On May 18, the U.
S.
FDA has approved the Phase III clinical trial of Prokruline for the treatment of hospitalized COVID-19 patients.
The second critical global multi-center phase III clinical trial approved by the FDA after the clinical trial
.

In short, the new crown epidemic is a serious public health challenge, but it is also an opportunity for some companies with technology and project reserves.
Their fate has been changed in the fight against the epidemic
.
It is also hoped that more companies can launch drugs with more diverse technologies to help the world respond and get rid of this haze as soon as possible
.